Department of Rehabilitation Medicine, NYU Grossman School of Medicine, 240 E 38th St 15th Floor, New York, NY, 10016, USA.
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Curr Neurol Neurosci Rep. 2023 May;23(5):213-224. doi: 10.1007/s11910-023-01263-5. Epub 2023 May 6.
This article reviews hypopituitarism after TBI, the importance of pituitary hormones, and related controversies, concluding with a suggested patient approach.
While earlier studies focused on increased pituitary deficiencies after moderate-severe TBI, recent studies have focused on deficiencies after mild TBI. There has been increasing focus on the role of growth hormone after injury; growth hormone is the most frequent reported deficiency at 1 year post-TBI, and an area with unresolved questions. While more research is needed to quantify the risk of deficiencies in special populations, and establish the natural history, increasing data indicate an increase in hypopituitarism after other acquired brain injuries; the potential role of pituitary hormone deficiencies after stroke and after COVID-19 infection is an area of active inquiry. Given the negative health effects of untreated hypopituitarism and the opportunity to intervene via hormone replacement, it is important to recognize the role of pituitary hormone deficiencies after TBI.
本文综述了创伤性脑损伤(TBI)后垂体功能减退的情况、垂体激素的重要性及相关争议,并提出了患者处理建议。
早期研究主要集中在中重度 TBI 后垂体功能减退增加,而近期研究则侧重于轻度 TBI 后垂体功能减退。目前,人们越来越关注损伤后生长激素的作用;生长激素是 TBI 后 1 年最常报告的缺乏症,也是一个存在未解决问题的领域。虽然需要更多的研究来量化特殊人群中缺乏症的风险,并确定自然病史,但越来越多的数据表明,其他获得性脑损伤后也会发生垂体功能减退;垂体激素缺乏症在中风和 COVID-19 感染后的潜在作用是一个活跃的研究领域。鉴于未治疗的垂体功能减退对健康的负面影响,以及通过激素替代进行干预的机会,认识到 TBI 后垂体激素缺乏症的作用非常重要。